Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.
Trial locations(16 sites)
Japan
Nagoya City University Hospital, Nagoya, Aichi-ken Fukushima Medical University Hospital, Fukushima, Fukushima Kagawa University Hospital, Kita-gun, Kagawa-ken Yokohama City University Medical Center, Yokohama, Kanagawa Kyoto University Hospital, Kyoto, Kyoto Mie University Hospital, Tsu, Mie-ken Nagasaki University Hospital, Nagasaki, Nagasaki University of the Ryukyus hospital, Ginowan-shi, Okinawa Kansai Medical University Hospital, Hirakata-shi, Osaka The University of Osaka Hospital, Suita-shi, Osaka Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka Jichi Medical University Hospital, Shimotsuke-shi, Tochigi Nihon University Hospital, Chiyoda-ku, Tokyo Tokyo Women's Medical University Hospital, Shinjuku-ku, Tokyo Toyama University Hospital, Toyama, Toyama University Of Yamanashi Hospital, Chuo-shi, Yamanashi